Fort L.P. bought a new position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 762 shares of the life sciences company’s stock, valued at approximately $34,000.
Other institutional investors have also recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its stake in Integra Lifesciences by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 112,264 shares of the life sciences company’s stock valued at $5,063,000 after acquiring an additional 1,805 shares during the period. Brown Advisory Inc. bought a new stake in Integra Lifesciences in the fourth quarter valued at about $45,653,000. Gideon Capital Advisors Inc. bought a new stake in Integra Lifesciences in the fourth quarter valued at about $471,000. Natixis Advisors L.P. increased its stake in Integra Lifesciences by 100.3% in the fourth quarter. Natixis Advisors L.P. now owns 68,396 shares of the life sciences company’s stock valued at $3,083,000 after acquiring an additional 34,245 shares during the period. Finally, Atlanta Capital Management Co. L L C increased its stake in Integra Lifesciences by 13.2% in the fourth quarter. Atlanta Capital Management Co. L L C now owns 728,155 shares of the life sciences company’s stock valued at $32,840,000 after acquiring an additional 84,944 shares during the period. 83.11% of the stock is owned by hedge funds and other institutional investors.
Shares of Integra Lifesciences stock opened at $56.01 on Friday. The company has a current ratio of 2.95, a quick ratio of 1.88 and a debt-to-equity ratio of 0.97. The stock has a market cap of $4.78 billion, a price-to-earnings ratio of 23.14, a PEG ratio of 1.63 and a beta of 0.96. Integra Lifesciences Holdings Corp has a 1-year low of $42.14 and a 1-year high of $67.50.
A number of analysts recently weighed in on the stock. JMP Securities reissued a “buy” rating and issued a $62.00 target price on shares of Integra Lifesciences in a research note on Wednesday, February 27th. Morgan Stanley set a $57.00 target price on shares of Integra Lifesciences and gave the company a “hold” rating in a research note on Friday, February 22nd. Cantor Fitzgerald reissued a “hold” rating and issued a $50.00 target price on shares of Integra Lifesciences in a research note on Thursday, February 21st. BidaskClub raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Wednesday, February 20th. Finally, Zacks Investment Research raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Monday, February 18th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $60.67.
In other Integra Lifesciences news, major shareholder Richard E. Caruso sold 30,128 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $56.06, for a total transaction of $1,688,975.68. Following the sale, the insider now directly owns 143,384 shares of the company’s stock, valued at $8,038,107.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 5.10% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://sportsperspectives.com/2019/03/17/fort-l-p-invests-34000-in-integra-lifesciences-holdings-corp-iart-stock.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Article: Should I follow buy, hold and sell recommendations?
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.